Table 1. Distribution of each variable in 1351 patients with non-malignant chronic liver diseases and HCC in the estimation group.
| |
Non-malignant chronic liver diseases (n=1124) |
|
|||
|---|---|---|---|---|---|
| Variablesa | F0c (N=107) | F1–F3c (N=676) | F4c (N=341) | HCC (N=227) | P-valueb |
| Age (years) |
37.2±8.7 |
42.7±7.9 |
46.1±7.6 |
59±10.3 |
<0.0001 |
| AST (U l−1) |
34.6±14.2 |
41.9±26.6 |
71±43 |
128± 109 |
<0.0001 |
| ALT (U l−1) |
40.2±23.1 |
49.6± 34.7 |
77.6±53.6 |
67.6±61.0 |
0.31 |
| AAR |
0.85±0.44 |
0.97±0.47 |
1.1±0.45 |
1.9±1.53 |
<0.0001 |
| ALP (U l−1) |
87.1±47 |
83.8±47.6 |
94±40 |
260±227 |
<0.0001 |
| Albumin (g l−1) |
43.9±3.5 |
42.7± 3.7 |
38±4.2 |
29 ±5.9 |
<0.0001 |
| Total bilirubin (mg dl−1) |
0.84±0.38 |
0.83±0.33 |
1.11±0.68 |
4.1±2.9 |
<0.0001 |
| Platelet count ( × 109 l−1) |
238±56 |
195±54 |
155±53 |
135±92 |
0.75 |
| Prothrombin-INR |
1.10±0.12 |
1.20±0.20 |
1.23±0.15 |
1.30±0.20 |
0.06 |
|
α-Fetoprotein (U l−1) |
2.3±1.1 |
0.58±0.44 |
38.8±21.2 |
32341±10109 |
<0.0001 |
| Log α-fetoprotein (U l−1) | 0.31±0.23 | 0.49±0.3 | 1.1±0.44 | 2.7±1.38 | <0.0001 |
Abbreviations: AAR=AST/ALT ratio; ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; HCC=hepatocellular carcinoma; INR=international normalised ratio.
a
Normal values: AST up to 40 U l−1; ALT up to 45 U lL−1; ALP 22–92 U l−1; albumin 38–54 g l−1; total bilirubin up to 1 mg% platelet count 150–400 ( × 109 l−1); and α-fetoprotein up to 10 U l−1.
b
P>0.05 is considered nonsignificant and P<0.05 is considered significant; the reference groups for P-values were HCC vs F4.
c
METAVIR score was used to stage fibrosis (F0–F3) and liver cirrhosis (F4).